Alnylam's Prospects Today
Though we've lowered our fair-value estimate of the drugmaker after it announced that it has stopped development of a key drug, we still believe in the potential of Alnylam’s remaining pipeline.
We are lowering our fair value estimate for Alnylam Pharmaceuticals (ALNY) significantly, to $50 per share from $90, after the unexpected discontinuation of phase 3 revusiran development. Revusiran is an RNAi drug for the treatment of familial amyloid cardiomyopathy, a hereditary disease where abnormal protein deposits gather in the heart and lead to heart failure. Before the announcement, revusiran was a key revenue driver in our Alnylam model. A higher incidence of patient deaths in the treatment arm of the revusiran study prompted the discontinuation, but is not expected to have bearing on the company’s other phase 3 trial, patisiran in familial amyloidotic polyneuropathy, which we anticipate will read out in 2017. Given the concentrated revenue drivers in early-stage biotech companies, we believe Alnylam still warrants a high uncertainty rating.
We still forecast break-even operating income in 2021 on the back of the successful launch of patisiran in 2018 (80% probability), although top-line revenue is expected to grow much more slowly given the loss of future revusiran contributions in our model. With Alnylam’s current rate of cash burn, we anticipate the company may need to raise additional capital before patisiran reaches the market. We still believe in the potential of Alnylam’s remaining pipeline, which includes fitusiran in hemophilia, ALN-CC5 in complement-mediated disorders, ALN-PCSsc for high cholesterol, and ALN-AS1 for hepatic porphyrias.
Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.
Kelsey Tsai does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.